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Developing of multi-target HIV-1 entry inhibitors represents an important avenue of drug therapy. Two such inhibitors are hexa-arginine-neomycin-
conjugate (NeoR6) and nona-D-arginine-neomycin-conjugate (Neo-r9). Our findings that NeoR6-resistant mutations appear in the gp120 constant regions;
and NeoR6 is not CCR5 antagonist, but inhibits CXCR4 and CCR5 HIV-1 using isolates, led us to suggest that NeoR6 may inhibit HIV-1 entry by
interfering with the CD4-gp120 binding. To support this notion, we constructed a homology model of unliganded HIV-1IIIB gp120 and docked NeoR6 and
Neo-r9 to it, using amultistep docking procedure: geometric–electrostatic docking byMolFit; flexible ligand docking byAutodock3 and final refinement of
the obtained complexes by Discover3. Binding free energies were calculated by MM-PBSA methodology. The model predicts competitive inhibition of
CD4-gp120 binding by NeoR6 and Neo-r9. We determined plausible binding sites between constructed CD4-bound gp120 trimer and homology modeled
membranal CXCR4, and testedNeoR6 andNeo-r9 interfering with this interaction. Thesemodels support our notion that another mechanism of anti-HIV-1
activity of NeoR6 is inhibition of gp120-CXCR4 binding. These structural models and interaction of NeoR6 andNeo-r9 with gp120 and CXCR4 provide a
powerful approach for structural based drug design for selective targeting of HIV-1 entry and/or for inhibition of other retroviruses with similar mechanism
of entry.
© 2007 Elsevier B.V. All rights reserved.Keywords: Hexa-arginine-neomycin-conjugate (NeoR6); poly-arginine-neomycin-conjugate (Neo-r9); Molecular modeling and docking; HIV-1 attachment inhibitor;
HIV-1 gp120; CD4/CXCR41. Introduction
Infection with the human immunodeficiency virus (HIV) starts
with the virus particle attachment to the cell surface followed by
viral membrane fusion with the target cell membrane, thereby
allowing entry of the viral genetic material into the cytosol [1,2].
The binding of the trimeric envelope glycoprotein gp120–gp41 to
the cell surface receptor CD4 and chemokine coreceptors CXCR4
or CCR5 triggers a series of conformational changes in the
envelope proteins. While performing distinct operations in HIV-1
entry, the activities of the gp120 and gp41 protomers must be
highly coordinated in order to lead to successful infection
(reviewed in [1,2]). Binding is enabled via the interaction of the⁎ Corresponding author. Tel.: +972 8 9343413; fax: +972 8 9344142.
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doi:10.1016/j.bbamem.2007.04.017mostN-terminal of the immunoglobulin-like domains of CD4with
a cavity in gp120 [3]. CD4 contacts all three gp120 core domains
and is thought to bring the inner and outer domains into proximity
and to structure the conformationally labile bridging sheet. Many
of the important contacts between gp120 and CD4 occur at the
interface of the three gp120 core domains. The binding of gp120
and CD4 creates a roughly spherical cavity at this location. This
cavity extends deep into the interior of gp120 and is bound by
residues from each of the gp120 core domains. These cavity-lining
gp120 residues are highly conserved among HIV-1 isolates. Thus,
CD4-binding cavity has been suggested as a potential target for
drug design [3,4]. The compounds that prevent HIV-1 gp120
binding to CD4 are called attachment inhibitors.
Previously our group has designed and synthesized a set of
novel peptidomimetic substances, conjugates of aminoglycoside
antibiotics with arginine [1,5–9]. The aminoglycoside-arginine
Fig. 1. (a) NeoR6 and Neo-r9. (b) NeoR6 and Neo-r9 in the bound conformation
with CXCR4.
Fig. 2. Schematic representation of the molecular modeling and the multistep
docking procedure followed in this study.
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serve as lead compounds for the development of multi-target HIV-
1 inhibitors [1]. The AACs, efficiently penetrate cells, including
neurons, and accumulate intracellularly [5–7,10]. The AACs
inhibit HIV-1 infection and proliferation in cultured human
lymphocytes, displaying low cytotoxicity [5,7,11], inhibit
gp120-triggered death in human neuroblastoma cells, and cross
the blood brain barrier [11]. Neomycin–arginine conjugate
(NeoR6, Fig. 1), designed as Tat-mimetic, functions also as
HIV-1 entry inhibitor by interacting with CXCR4 [7,11–13] at the
binding site of the anti-CXCR4 mAb 12G5 [7]. The interaction
between HIV-1 and CXCR4 involves the variable 3 (V3) loop of
gp120 [14]. SinceNeoR6 is a V3mimetic, comprising six arginine
moieties, it may also compete with the gp120 V3 loop for CXCR4receptor binding and thus inhibit entry of HIV-1 into cells. The
crystal structure of V3 loop in the context of an HIV-1 gp120 core
complexed to the CD4 receptor and to the X5 antibody was
recently determined [15]. These structures provide a structural
rationale for the role of V3 loop in HIV-1 entry and evasion of the
immune system [15]. Of note, we found in NeoR6 resistant
(NeoR6res) viral isolates mutations in the constant regions C3 and
C4, and in the variable region V4 of gp120 and 2 mutations in the
heptad repeat 2 (HR2) of gp41 [16]. Importantly, two of the three
gp120 mutations (I341T and Q398K) are located in the CD4-
binding cavity of gp120. These results led us to suggest that
NeoR6may also inhibit HIV-1 entry by interferingwith the gp120-
CD4 binding and with the pre-hairpin intermediate of the fusion
process [16].
Recently, we synthesized a novel set of D- and L-poly-arginine
aminoglycoside conjugates (pAACs) and their antiviral activities
are currently being investigated [8]. Our findings indicate that the
most potent pAAC, nona-D-arginine-neomycin-conjugate (Neo-r9,
Fig. 1) inhibits a variety of T-tropic HIV-1 isolates, including
NeoR6res isolates. Since Neo-r9 has a relatively similar structure to
NeoR6, we suggested that, as well as NeoR6, it may also inhibit
HIV-1 entry by interfering with CD4-gp120 and gp120-CXCR4
bindings. Moreover, because Neo-r9 is significantly more
positively charged than NeoR6, we predict that it can interact
also with the gp120 residues of NeoR6res strains.
There are a number of drugs whose development was heavily
influenced by or based on structure-based design and screening
strategies, such as HIV-1 protease inhibitors [17]. Computational
methodologies have become a crucial component of many drug
discovery programs, from hit identification to lead optimization,
approaches such as ligand- or structure-based virtual screening
Fig. 3. (a) Data of mutagenesis experiments [20]. HIV-1 gp120 (IIIB isolate) shown as a ribbon with the residues corresponding to inhibitor-resistant mutations in CPK
representation. NeoR6-resistant mutations colored gray. BMS-378806-resistant mutations colored black. (b) Epitopes (IIIB gp120 residues 430–470) of anti-gp120
antibodies [21]. Residues of epitopes are shown in CPK representation. NeoR6-resistant mutations colored gray. (c) Conserved epitope of neutralizing mAb b12. The
gp120 (PDB entry 2ny7, chain g [41]) is shown as lines representation with residues that interact within 4 Å of b12 in CPK representation. (d) Residues of unliganded
HIV-1IIIB gp120 corresponding to b12 epitope shown in CPK representation. (e) 4KG5 discontinuous epitope [42] on our model of unliganded gp120 trimer. One
protomer is shown black; a second in gray. The residues of V1–V2 loop of the first protomer and residues of V3 loop of the second one, participating in mAb binding,
are shown in CPK representation.
2109A. Berchanski, A. Lapidot / Biochimica et Biophysica Acta 1768 (2007) 2107–2119techniques are widely used in many discovery efforts [17]. When
the structure of a target is available, docking is primarily used as a
hit-identification tool. Docking is often also used later on during
lead optimization, when modifications to known active structures
can quickly be tested in computer models before compound
synthesis [18]. The main purpose of our present study is predicting
the bindingmode of NeoR6 andNeo-r9. Successful prediction of a
ligand binding mode in a protein active site is perhaps the most
straightforward in the area of computational drug discovery
process [18]. We used a multistep docking approach (Fig. 2)
containing: (i) geometric–electrostatic docking full scan byMolFit
with the following post-scan filtering for prioritizing of the
possible binding sites; (ii) flexible ligand docking by Autodock3
for finding the correct poses of ligands within formerly determined
binding sites; and (iii) final refinement of the obtained complexes
by Discover3. Binding free energies were calculated byMolecular
Mechanics Poisson–Boltzmann surface area (MM-PBSA) meth-
odology. Docking studies of putative drugs with the previously
available HIV-1 gp120 structures representing the CD4-bound
state [e.g. [3,15]] have some limitations in light of the significant
conformational changes that occur in gp120 upon CD4 binding
[4]. Comparison between the crystal structure of the unliganded
simian immunodeficiency virus (SIV) gp120 [19] and of HIV-1
gp120 structure in complex with CD4 receptor [3,15] reveals that
receptor binding induces large conformational changes in gp120
[15].We here propose that NeoR6 and Neo-r9 competitively inhibit
the CD4-gp120 binding in unliganded conformation and predict
their binding sitemapped to theCD4binding region.We undertook
a molecular modeling study constructing structures of unliganded
HIV-1 gp120, CD4-bound gp120 trimer, CXCR4 andNeoR6/Neo-
r9 docking for better understanding the mechanisms for their
interference in the CD4-gp120 and gp120-CXCR4 interactions.
2. Methods
We constructed a homology model of unliganded HIV-1IIIB gp120 and
docked NeoR6 and Neo-r9 to it using a multistep docking procedure:
geometric–electrostatic docking full scan by MolFit; flexible ligand docking
by Autodock3 and final refinement of the obtained complexes by Discover3
(Fig. 2).
2.1. Homology modeling
Homology models of unliganded HIV-1 glycoproteins gp120, from IIIB and JR-
FL isolates, were generated using the “Homology” module of InsightII (Accelrys,
Inc., San Diego, CA, USA), and the 3D coordinates of unliganded SIV glycoprotein
gp120 (PDB entry 2bf1 [19]) as a template. The loops in which inserts or deletions
occurwere generated using “Homology”module. The initial loopswere then checked
for clashes that were eliminated by selecting different rotamers for the side chains. In
general, all the energyminimization andmolecular dynamics simulations in this study
were performed formolecules immersed in a layer of 5Å ofwater until themaximum
derivative was less than 0.001 using the “Discover 3” module of InsightII and the
CVFF force field. The modeled structure (including generated loops) was further
optimized by 20 intermittent minimization and molecular dynamics stages.
Table 1




CD4-gp120 a (JR-FL isolate, PDB entry 2b4c) NeoR6-gp120 (IIIB isolate) Neo-r9-gp120 (IIIB isolate) BMS-378806 b
(YU2 isolate)
C1 Pro124, Cys126, Ala129 Rhe63, Trp66
C2 Asn279, Asn280, Ala281, Thr283 Lys252 Val255, Ser256, Thr257
C3 Ser365, Gly366, Gly367,
Asp368, Glu370, Ile371
Lys327, Thr328, Ile329, Ile330,
Phe331, Lys332, Gly336,
Gly337, Asp338, Glu340 c, Ile341
Ile329, Ile330, Phe331, Gln333,
Ser335, Gly336, Gly337,
Asp338, Glu340c, Ile341, Val342
Glu370c, Ser375
V4 Glu373




Gln398, Glu399, Asp427 Phe393, Asn395c, Met396c,
Trp397c, Gln398, Glu399,
Val400c, Gly401c, Asp427, Gly429
Ile424, Asn425c, Met426c,
Trp427c, Val430c, Gly431c
V5 Ile460, Arg469 Asn431, Glu434, Glu436 Asn430, Asn431, Glu434, Glu436
C5 Gly472, Gly473, Asp474, Asp477 Gly473, Asp474, Met475
The gp120 residues which are mutated in the NeoR6res isolates are underlined. Common HIV-1 gp120 residues for CD4 and NeoR6, Neo-r9 and BMS-378806 binding
are marked in bold.
a [15].
b [51].
c Common gp120 residues participating in Neo-r9 (and/or NeoR6) and BMS-378806 binding.
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construction of the model. The IIIB gp120 with mutations I341T and Q398K, was
modeled by replacing the side-chains of these residues using the “Biopolymer”
module of InsightII. The model of the mutant gp120 was further energy minimized,
being the C atoms of mutant gp120 constrained to their initial positions. An
approximatemodel ofHIV-1IIIB unliganded gp120 trimerwas created by applying the
rotation matrices and vectors of translation taken from PDB entry 2bf1 [19].
Mutagenesis and antigenic reactivity experiments were used to validate the
unliganded HIV-1 gp120 homology model (using HIV databases accessed through
the NIH AIDS reagent program, (http://www.aidsreagent.org/, [20,21])) (Fig. 3).
In the present study the amino acid numbering of IIIB gp120 is based on the
sequence presented in [22]. It is different from the amino acid numbering of JR-FL
gp120 (PDBentry 2b4c, chain g [15]) by 30 residues. For example, Ile341 andQ398
of IIIB gp120 correspond to Ile371 (341+30=371) and Gln428 (398+30=428) of
JR-FL gp120, respectively. This relation approximately stands for all the residues of
these two sequences (Tables 1 and 2).
Homology model of CXCR4 was constructed by the same procedure as for the
unliganded gp120, using the “Homology” module of InsightII, and the 3D
coordinates of bovine rhodopsin (PDB entry 1l9h [23]) as a template. Two disulfide
bridges Cys28–Cys274 and Cys109–Cys186 of CXCR4 were used as distance
restraints in the construction of the model.
2.2. Full rigid-body docking of NeoR6 and Neo-r9 to gp120 and CXCR4
NeoR6 and Neo-r9 models were constructed by addition of arginines to
neomycin B (its 3D coordinates were taken from PDB entry 1qd3 [24]). This PDB
entry contains 17 NMR conformers which substantially differ one from another. We
used the first NMR structure from1qd3 andmost different conformer of neomycinB
(with root mean square deviation (RMSD) of 2.5 Å between them) for the ligand
construction. NeoR6 and Neo-r9 were docked to gp120 and CXCR4 using the
program MolFit (kindly provided by Dr. M. Eisenstein; [25,26]). MolFit treats the
molecules as rigid bodies. They are represented by 3D grids in which each grid point
carries information concerning its position with respect to the surface/interior of the
molecule. The surface grid points carry chemical information such as theTable 2
HIV-1 V3 loop sequence
Isolate V3 sequence
JR-FL 296-CTRPNNNTRKSIhI-GPGRAFyTtGeiIGd i RQAHC-331
IIIB 266-CTRPNNNTRKSIrIqrGPGRAFvTiGk-IGnmRQAHC-301
The conserved residues are shown in uppercase, with variable residues in lowercase.electrostatic potential or the hydrophobicity of the surface. MolFit performs an
exhaustive scan of the relative rotations and translations of the molecules and
produces a list of models. Since gp120 and CXCR4 consist of many negatively
charged residues, while NeoR6 and Neo-r9 are highly positively charged
compounds, we performed full geometric–electrostatic scans [27] of these ligands
against gp120 and CXCR4. The electrostatic potential of each molecule was
calculated using the program Delphi as implemented in the InsightII package. Each
full docking scan tested 8760 relative orientations (angular grid interval of 12°) and
for each orientation the best scoring solutionwas saved. These solutionswere further
sorted by their geometric–electrostatic complementarity score. After docking scans,
the carbohydrates were manually added to the appropriate glycosylation sites at the
gp120IIIB [22]. The results of each scan were filtered in a manner that the MolFit
solutions which have contacts with glycosyls were omitted from the list.
2.3. Flexible docking of NeoR6 and Neo-r9 to gp120 and CXCR4
The geometric–electrostaticMolFit scan solutionswere used for input to flexible
ligand docking program AutoDock3 [28]. We tested four possible binding sites of
NeoR6 to gp120 formed by MolFit clusters 3–6 and two putative binding sites of
NeoR6 to CXCR4 formed by clusters 1 and 2. For NeoR6 docking, a grid spacing of
0.375 Å and 60×60×60 number of points was created. Neo-r9 comprises a long
chain of nine arginine moieties, spanning on a larger space than NeoR6. Thus we
used a grid spacing of 0.2Å and 128×128×128 number of points. Other Autodock3
parameters were used as default. The aminoglycoside rings were defined as fixed
roots. Since themaximumallowed is 32 active torsions, five or six active torsions per
side-chain of each arginine moiety were permitted for NeoR6 and 3–4 active
torsions per side-chain for Neo-r9.
The final refinement of top-scored docking conformations obtained from
Autodock3 was performed by energy minimization using Discover3. The
intracellular domains and transmembrane helices of CXCR4 were fixed, except
for several residues that are close to N-terminus and extracellular loops. The
energy of the finally refined complexes was measured by “Docking” module of
InsightII according to maximal radii of ligands.
The binding free energies were calculated by MM-PBSA method
implemented in Amber9 program package [29,30].
2.4. Modeling of CD4-gp120 trimer-CXCR4 complex
According to Basmaciogullari [14] gp120 β19 strand and V3 loop contain
residues important forCXCR4 interaction. TheV3 loop is absent in almost all crystal
structures of gp120, except PDB entry 2b4c [15]. However, this gp120 is from a JR-
FL isolate which interacts with the CCR5 coreceptor and not with CXCR4.
Table 3




gp120 according to previous studies a gp120 according to our model NeoR6 Neo-r9
Nter Glu2, Tyr7, Asp10, Tyr12,
Glu15, Asp20, Tyr21, Asp22,
Ser23, Glu26, Glu32
Glu2, Ser5, Ile6, Tyr7, Tyr12,
Thr13, Glu14, Met16, Gly17,
Ser18, Gly19, Asp20, Tyr21,
Asp22, Ser23, Met24, Lys25, Glu26
Asp22, Ser23, Pro27 Glu2, Asp22, Met24
EL1 Phe104, Phe107 Gly105, Asn106, Phe107, Leu108 Phe104, Gly105
EL2 Asn176, Glu179, Asp182, Arg183,
Tyr184, Asp187, Arg188, Phe189,










Pro191, Asn192, Asp193, Leu194
EL3 Asp262, Glu268, Gln272, Glu277 Asp262, Ser263, Phe264,
Ile265, Leu267, Glu268
Common CXCR4 residues for gp120 binding, according to previous studies and to our model are underlined. Common CXCR4 residues for gp120 binding and NeoR6
(and/or Neo-r9) are marked in bold.
a [35–40].
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corresponding fragment from 2b4c by substituting the relevant residues (Table 2).
The core of gp120 structure was not changed.
Construction of the CD4-bound gp120 trimer was performed using a Cn
oligomer-forming algorithm. This prediction procedure includes a symmetry-
restricted docking step followed by a Cn oligomer-forming step, in which the dimers
from the docking step are assembled to oligomers under given symmetry constrains
[31]. The docking step of Cn oligomer-forming algorithm was performed using the
programMolFit. In the current study we performed a symmetry restricted (allowing
only rotations of 360°/3=120°) weighted geometric rotation/translation docking
scan [32] of one gp120 protomer against its copy. According to Kwong and
colleagues [33], conserved exposed residues 195–210 are important in protomer–
protomer contact in the gp120 trimer; we therefore up-weighted contacts involving
these residues. The angular interval of 12° and the 3-fold symmetry restriction
resulted in 1738 relative orientations and for each orientation the best scoring
docking solution was saved. These homodimers were then used in the Cn oligomer-
forming step. The additional symmetry constraints (the angle between the
eigenvector of the protomer–protomer rotation matrix and the protomer–protomer
translation vector must be approximately 90°) reduced the number of possible
trimers to 167. The top ranking gp120 trimerwas used for furthermodeling of CD4–
gp120 trimer–CXCR4 complex.
The three structures of four-domain CD4s (PDB entry 1wio [34]) were
superimposed onto the common Cα atoms of two-domain fragments of CD4s (PDB
entry 2b4c, chain c [15]). Next, the modeled trimeric gp120–CD4 complex was
placed near the CXCR4 with the V3 loop and β19 strand of CD4-bound protomer
contacting the CXCR4 residues, which participate in the CXCR4–gp120 binding
[35–40] (Table 3). The majority of the gp120 protomer residues were constrained in
the energy minimization of the CD4-bound gp120 trimer–CXCR4 complex, except
for residues of the V3 loop and β19 strand. The intracellular domains and
transmembrane helices of CXCR4 were fixed, except for several residues that are
close to the N-terminus and extracellular loops.
3. Results
3.1. Interference of CD4–gp120 interaction by NeoR6
Previously we found in NeoR6res isolatesmutations in gp120 at
the regions C3, C4, and V4 [16]. Also our experimental findings
proved that NeoR6 does not inhibit the mAb 2D7 binding with
CCR5 [7], and does not competewithCCR5 chemokineRANTES
[13], suggesting that NeoR6 is not a CCR5 antagonist. However,
NeoR6 inhibits HIV-1 JR-FL and Ba-L CCR5-using isolates with
50% effective concentration (EC50) values at the range of 0.8–
5 μM, similar to that of CXCR4-using isolates [7]. These resultsled us to suggest that NeoR6 may also inhibit HIV-1 entry by
interfering with the gp120–CD4 binding [7].
3.1.1. Validation of gp120 model
Significant conformational changes in gp120 occur upon CD4
binding (Fig. 4a, b). We suppose that NeoR6 and Neo-r9 bind
gp120 prior to CD4–gp120 assembly. Thus, we constructed
unliganded HIV-1IIIB gp120 core using the unliganded SIV gp120
(PDB entry 2bf1 [19]) as a template. The gp120 cores of SIVand
HIV-1 have 35–37% sequence identity and over 70% sequence
similarity (depending on the HIV-1 isolate); alignment of these
sequences is unambiguous [19]. These proteins have conserved
disulfide bonds and nine of the glycosylation sites on SIV protein
and on the HIV-1 protein are conserved or shifted by no more than
one or two residues [19]. Published data of mutagenesis and
antigenic reactivity experiments [20,21] were used to validate our
unliganded HIV-1 gp120 homology model. 53 inhibitor-resistant
mutations are located in our gp120 model. All these gp120
residues are solvent accessible and available for direct ligand
interaction in our unliganded HIV-1IIIB gp120 modeled protomer
(Fig. 3a). Moreover, most of these residues are available also in the
approximate model of the HIV-1 unliganded trimer constructed by
us according to the model of its SIV counterpart [19]. The
accessibility of the residues of our model to the antibodies was
checked. According to HIV Molecular Immunology Database
[21], almost all known epitopes are solvent accessible and
available for direct interaction in our model. For example, the
HIV-1IIIB gp120 residues 330–370 (which correspond to HXB2
residues 360–400, that are located in proximity of NeoR6-resistant
mutations), relating to epitopes of antibodiesC12, 36.1 (ARP329),
4D7/4, B32, 110.D, B34, and B15, are shown at Fig. 3b. It was
shown by Zhou and colleagues [41] that the X-rays crystallo-
graphic structure of the broadly neutralizing antibody b12 in
complex with the created gp120 variant stabilized in the CD4-
bound state. The gp120 residues located within 4 Å of b12 are
shown at Fig. 3c. These residues form almost a contiguous surface
in the CD4-bound conformation, but map to a more distributed
surface on our model of unliganded gp120 (Fig. 3d). MAb 4KG5
has a discontinuous epitope that jointly binds to V1–V2 and V3
Fig. 4. The binding site of CD4 and putative binding sites of NeoR6 and Neo-r9 on gp120. (a) Structural model of unliganded HIV-1 gp120 (JR-FL isolate). The gp120 is
shown as a green ribbon. Residues that participate in CD4 binding are depicted in CPK representation (detailed list of these residues is shown in Table 1). The residues Ile371
andGln428 (JR-FL isolate), shown inmagenta, correspond to the Ile341 andGln398 residues of IIIB gp120. CD4 is colored cyan. (b) CD4–gp120 complex. The gp120 (PDB
entry 2b4c, chain g [15]) is shown as a green ribbonwith residues that interact within 4ÅofCD4 inCPK representation. The residues Ile371 andGln428 are shown inmagenta.
The fragment of CD4 receptor (PDB entry 2b4c, chain c [15]) is shown in stick representation and colored in cyan. (c) An approximate model of HIV-1IIIB unliganded trimer
and results of the geometric–electrostatic docking scans for NeoR6 and Neo-r9. The three protomers are in blue, green and red, respectively. Each MolFit solution is the
plausible position of ligand onmacromolecule, represented by the center of ligandmass (colored sky blue for NeoR6 and orange for Neo-r9). The six clusters of NeoR6MolFit
solutions are labeled in black; the three clusters of Neo-r9 are labeled in blue. (d) The complex betweenNeoR6 andmodeled unligandedHIV-1 gp120 (IIIB isolate). The gp120
is shown as a green ribbonwith critical residueswithin 4Å ofNeoR6 inCPK representation. The negatively charged residues are shown in red. The neomycin core ofNeoR6 is
shown in yellow, and the argininemoieties are in sky blue. The residues Ile341 andGln398 are shown inmagenta. The competition betweenNeoR6 andCD4 receptor at this site
is suggested. ThemeanRMSDbetween ten ligand structures of the refined complexes is 1.005Å. (e) The complex betweenNeo-r9 and unligandedHIV-1 gp120 (IIIB isolate).
The colors are as in panel d. The mean RMSD between ten ligand structures of the refined complexes is 1.32 Å.
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other, and it is not likely that 4KG5 antibody could contact them
simultaneously. Our model of HIV-1IIIB gp120 trimer in the
unliganded conformation, as well as the trimer model, constructed
by Chen and colleagues [19], show that the V1–V2 from one
protomer contacts the V3 loop of another protomer. It is plausible
that these loops from different protomers within the trimer form an
epitope for 4KG5 (Fig. 3e). As far we know, this is the first
unliganded HIV-1 gp120 homology model.
3.1.2. Full geometric–electrostatic docking of NeoR6 to
unliganded HIV-1IIIB gp120
We performed full geometric–electrostatic docking scan of
NeoR6 against modeled HIV-1IIIB gp120 using the program
MolFit (seeMethods and Fig. 2). Each predictedMolFit solution
is the plausible position of NeoR6 on gp120. The post-scan
filtering was performed with the purpose to delete docking
solutions which are overlapping with glycosyls. Filtering
revealed six clusters of MolFit solutions (Fig. 4c). In line with
our approximate model of the HIV-1 unliganded trimer, two out
of these clusters (1 and 2) are located at the regions interacting
with the neighboring protomer, making these two sites
inaccessible for ligands (Fig. 4c). The top ranking solutionafter post-scan filtering is located at cluster 3. This cluster and
cluster 4 adjacent to it are situated at the CD4-binding region of
gp120, which includes the site of NeoR6-resistant mutations
I341Tand Q398K (Fig. 4c). The cluster 3 consists of more high-
scoring docking solutions than clusters 4, 5 and 6.
3.1.3. Flexible docking NeoR6 to unliganded HIV-1IIIB gp120
The best-scoring representatives of predicted MolFit clusters 3,
4, 5, and 6were used for flexible docking performed byAutodock3
(see Methods and Fig. 2). The ranges of final docked energies for
NeoR6 are: from −17.0 to −13.43 kcal/mol at the cluster 3 and
from −6.01 to −0.78 at the other clusters. Next, the top ranking
Autodock3 solutions for each putative site were refined by energy
minimizations. The NeoR6–gp120 complex with the lowest
energy (−283 kcal/mol) was obtained at the CD4 binding site
(Fig. 4d, Table 1). All six arginine residues of NeoR6 have
electrostatic interactions with gp120 residues via their guanidino
groups with Asp338, Glu340, Glu399, Asp427, Glu434 and
Glu436; neomycin core also tightly interacts with gp120 residues.
The refined complexes between NeoR6 and gp120 at the sites
derived from clusters 4, 5, and 6 revealed significantly higher
interaction energy (from −165 to −33 kcal/mol), indicating that
the interactions of NeoR6 with these sites are less favorable, than
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binds gp120 preferably at the CD4 binding site than at the other
possible sites.
Gp120 with mutations I341T and Q398K was modeled by
replacement of the native side-chains of Ile341 and Gln398
residues by Thr and Lys, respectively. We performed the same
docking procedure for NeoR6 and mutant gp120 as for wt-gp120
(IIIB isolate). While mutation I341T causes steric hindrance,
mutation Q398K in the NeoR6res isolates causes electrostatic
repulsion which significantly weakens NeoR6 binding to gp120.
Indeed, the finally refined NeoR6–mutant gp120 complexes was
much less energetically favorable (−135 kcal/mol).
3.2. Predicted interference of CD4–gp120 interaction by Neo-r9
The new HIV-1 entry inhibitor Neo-r9 structurally resembles
NeoR6. A variety of T-tropic HIV-1 isolates, including NeoR6res
strains are sensitive to it, thus we predict that Neo-r9 may also
inhibit gp120–CD4 interaction. To examine this hypothesis, we
applied the same docking procedure for Neo-r9 as for NeoR6. The
full geometric–electrostatic docking scan of Neo-r9 against
modeled HIV-1IIIB gp120 with post-scan filtering revealed three
clusters of MolFit solutions (Fig. 4c). According to our model of
unliganded trimer, cluster 1 is located at the region interactingwith
the V3 loop of the neighboring protomer, making this site
inaccessible for ligand binding (Fig. 4c). Two remaining clusters (2
and 3) are located at the CD4-binding region of gp120, which
includes the site of NeoR6-resistant mutations I341T and Q398K
(Fig. 4c). The top ranking solution after post-scan filtering is
located at cluster 3.
The best-scoring representatives of these two clusterswere used
for flexible docking performed by Autodock3. The ranges of final
docked energy for Neo-r9 are: from −12.45 to −0.93 kcal/mol at
the cluster 2; and from −19.28 to −0.78 at the cluster 3. Neo-r9 at
both positions has contacts with I341 andQ398, which are located
at CD4 binding site. The top rankingAutodock3 solutions for each
putative site were refined by energy minimizations. The Neo-r9–
gp120 complex with the lowest energy (−2556 kcal/mol) was
obtained at the CD4 binding site (Fig. 4e, Table 1). Seven arginine
residues of Neo-r9 have electrostatic interactions with gp120
residues via their guanidino groupswith Asp338,Glu340, Glu373,
Glu399, Asp427, Glu434, andGlu436; neomycin core also tightly
interacts with gp120 residues. Thus, the docking results reveal that
Neo-r9 binds gp120 preferably at the CD4 binding site. Interaction
energy of−2527 kcal/molwas found for the best complex between
Neo-r9 and gp120 with NeoR6res mutations I341T and Q398K,
that is similar to results of Neo-r9–wt-gp120IIIB complex
(−2556 kcal/mol). Thus, the influence of these mutations on
Neo-r9 docking to gp120 was less significant than for NeoR6.
3.3. Validation and accuracy of the CXCR4 model
CXCR4 and bovine rhodopsin have 23% sequence identity
and 40% sequence similarity. However, the sequence of
hydrophobic transmembrane (TM) helices are similar in these
proteins, allowing the construction of the CXCR4 core with high
level of accuracy. The main problem is the construction of the N-terminus and three extracellular loops (EL1–EL3), which are
very variable. As recently reported [36,43,44], we also used an
approach combining molecular modeling and experimental
validation. At least three reasonable models of CXCR4 were
reported by these groups. Importantly, two previously reported
disulfide bridges Cys28–Cys274 and Cys109–Cys186, found
experimentally [45], are essential for constructing the CXCR4
model. The importance of Arg188–Glu277 salt bridge in a
CXCR4 model was recently reported [43]; we also found in our
model similar distances between these residues (∼7 Å). The
polar residues of the extracellular domains of CXCR4 were
exposed to water and the TM helices were stabilized by multiple
hydrogen bonds and non-bonded interactions in our model.
Most of the CXCR4 residues that participate in gp120 binding
are solvent accessible and available for direct ligand interaction
in our CXCR4 model [35–40,44].
All together, the experimental findings regarding the structure
of CXCR4 and its ligand binding, found by other groups [35–
40,43,44] and by us, are consistent with ourmodel, suggesting that
it is appropriate for further docking investigations.
3.4. Modeling of CD4–gp120 trimer–CXCR4 complex
Lapidot and colleagues showed that NeoR6 functions as HIV-1
entry inhibitor by interfering with gp120–CXCR4 binding [7,11–
13], suggesting its competition with the gp120 V3 loop. Thus, it
was of interest to construct amodel for identifying gp120 plausible
binding site on CXCR4. For this purpose, we constructed a model
of CD4–gp120 trimer–CXCR4 complex.
Constructing a model of three CD4 molecules bound gp120
trimer may provide additional information in determination of
putative gp120–CXCR4 binding site. We did not perform
molecular dynamic simulation for transition from unliganded
gp120 trimer to its CD4-bound trimer. We used the unliganded
HIV-1IIIB gp120 homology model for construction of trimer by
applying the rotationmatrices and vectors of translation taken from
PDB entry 2bf1 [19]. The unliganded HIV-1IIIB gp120 trimer is
shown in Figs. 4c and 5a. The CD4-bound conformation of gp120
trimer was created by the Cn oligomer-forming algorithm [31]
using crystal structure of CD4-bound gp120 (PDB entry 2b4c).We
modeled the V3 loop according to HIV-1IIIB gp120 sequence,
whereas the core of gp120 structurewas not changed (Fig. 5b). The
overall shape of our top ranking trimer was similar to the trimer
modeled by Kwong and colleagues [33]. The trimers ranked 9, 27,
and 37 by Cn oligomer-forming algorithm were similar to the top
ranking trimer.
CD4 receptor binds obliquely to the sides of the gp120
trimer, with its third and fourth domains being almost parallel to
the host cell membrane [15,33]. This relation is similar to our
obtained CD4-bound gp120 trimer complex (Fig. 5d). We
assumed that the plane defined by the 3 Cα atoms of the CD4
last ordered residues (prior to their transmembrane-spanning
regions), in the modeled CD4-bound gp120 trimer complex,
form a plane which is parallel and very close to the plane of the
host cell membrane. This plane was used as approximation of
the membrane plane for construction of overall CD4-bound
gp120 trimer–CXCR4 assembly.
Fig. 5. (a) Structural model of HIV-1IIIB unliganded trimer. Position of V3 loops (colored blue, in CPK representation) andβ19 strands (coloredwhite, CPK representation) on
our model. The three protomers are in green, gray and orange, respectively. The bases of V3 loops are in red. View from the target molecule. (b) The shape of one CD4-bound
gp120 protomer is shown as a ribbon. All residues of V3 loop and β19 strand are exposed for direct ligand interactions. The colors and representation are as in
panel a. (c) Structural model of the CD4-bound gp120 trimer. View, representation and colors are as in panel a. (d) Structural model of CD4–gp120 trimer–CXCR4 complex.
TwoCD4molecules (1wio [34]) are colored in cyan (thirdCD4 is not shown for clarity), protomers ofmodeled gp120 trimer are colored in orange, gray and green, andCXCR4
is colored in yellow. The V3 loop of CD4-bound gp120 protomer, which binds to CXCR4, is shown in stick representation, with arginines and lysines colored in cyan. The
CXCR4 residues that are important in gp120 binding [35–40] are shown in CPK representation, as listed in Table 3. Negatively charged CXCR4 residues are colored red; all
other are in white. NeoR6-resistant mutations in two frontal protomers of gp120 trimer are shown in CPK representation and colored magenta. (e) The NeoR6–CXCR4
complex. CXCR4 is shown as a yellow ribbon with critical residues within 4 Å of NeoR6 depicted in CPK representation. The negatively charged residues are shown in red.
The NeoR6 is shown in ball-and-stick representation and colored sky blue. The inhibition of gp120–CXCR4 binding by NeoR6 at this site is suggested. The mean RMSD
between ten ligand structures of the refined complexes is 1.43 Å. (f) The Neo-r9–CXCR4 complex. The colors are as in panel d. The inhibition of gp120–CXCR4 binding by
Neo-r9 at this site is suggested. The mean RMSD between ten ligand structures of the refined complexes is 1.73 Å.
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complex form an almost continuous high negatively charged
surface (Fig. 5e). It was reported that the gp120 β19 strand and
V3 loop contain residues important for CXCR4 interaction [14].
Taken together all these considerations, we placed our model of
CXCR4 close to the modeled CD4-bound gp120 trimer complex
in a manner that: (1) the TM helices of CXCR4 must be roughly
parallel to the trimer axis; (2) the TM helices of CXCR4 are
approximately perpendicular to the plane host cell membrane;
(3) V3 loop is close to CXCR4 EL1 and EL2; and (4) β19 strand
is close to the N-terminus of CXCR4. The complex between
gp120 protomer and modeled CXCR4 in the context of CD4–
gp120 trimer–CXCR4 complex was energyminimized. Accord-
ing to our model the CXCR4N-terminus reaches up and binds to
the gp120 core, including β19 strand and V3 loop base, while
the V3 loop reaches down to interact with EL1 and EL2 (Fig.
5d). The V3 loop coreceptor binding tip protrudes 30 Å from thecore toward the host cell membrane [15], this is also found in our
model (Fig. 5d).
According to our model, Arg268, Lys275, Arg278, Arg281,
Arg285, Lys292, Arg297 of gp120 V3 loop form electrostatic
interactions with CXCR4 N-terminal and EL2 Glu14, Asp22,
Glu2, Glu179, Asp181, Glu26, Asp20, respectively (Table 3). The
other V3 loop residues have multiple van der Waals interactions
with CXCR4 residues of the N-terminus, EL1 and EL2.
3.5. Interference of gp120–CXCR4 interaction by NeoR6 and
Neo-r9
Structural mimicking of the V3 loop byNeoR6 andNeo-r9 can
be easily achieved due to the flexibility of these compounds.
Docking of NeoR6 and Neo-r9 to CXCR4was performedwith the
same procedure as for gp120 (without post-scan filtering). The
geometric–electrostatic docking of NeoR6 and Neo-r9 revealed
Table 4




NeoR6 1st conformer −63.1 −22.7 −74.2
NeoR6 2nd conformer −65.4 −21.3 −78.6
Neo-r9 1st conformer −83.5 −79.4 −97.1
Neo-r9 2nd conformer −80.9 −75.3 −97.6
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The top ranking solutions of geometric–electrostatic scans for
these compounds formed a cluster in this region, and they were
used for docking performed by Autodock3. The ranges of final
docked energy for NeoR6 are from −18.0 to −9.19 kcal/mol and
for Neo-r9 are from −29.45 to −19.48 kcal/mol. The complexes,
obtained from Autodock3 scans, were refined by energy
minimizations. The final NeoR6–CXCR4 (shown in Fig. 5e,
Table 3) and Neo-r9–CXCR4 (Fig. 5f and Table 3) complexes
have energy of −413 kcal/mol and of −3611 kcal/mol,
respectively. All arginine residues of NeoR6 and Neo-r9 have
multiple interactions (mostly electrostatic) with CXCR4 residues
of N-terminus, EL1, and EL2, including 4 and 8 negatively
charged residues, for NeoR6 and Neo-r9, respectively. The
neomycin core of these compounds also tightly interacts with
CXCR4 residues. According to our results, 10 CXCR4 residues
are common for bindingwithNeoR6 and gp120;while 14 forNeo-
r9 and gp120 (Table 3). This model further lends support to the
notion that another mechanism of action of anti-HIV-1 activity by
NeoR6 and Neo-r9 is interference of gp120–CXCR4 interaction.
4. Discussion
Can the interaction of NeoR6 with gp120, suggested by our
model, explain inhibition of HIV-1 gp120 attachment to CD4?
According to our structural model and docking results, eight
residues of CXCR4 (Gly336, Gly337, Asp338, Glu340, Ile341,
Gln398, Glu399, Asp427) are common for gp120 binding with
NeoR6 and CD4 (Table 1). The model structure of NeoR6–gp120
complex explains our experimental findings that NeoR6res isolates
have themutations I341Tand Q398K in gp120 [16]. It is plausible
that NeoR6 directly interacts with Ile341 and Gln398. This model
further lends support to the notion, based on our experimental
studies [7,13,16], that one of the mechanisms of action of anti-
HIV-1 activity by NeoR6 is inhibition of gp120–CD4 binding.
Thus, NeoR6 may be a prototype for design of new HIV-1
attachment inhibitors (such as Neo-r9).
The possibility if another, most different, conformer of
neomycin B (RMSD of 2.5 Å between them) used for ligand
construction, can influence on the docking results, was examined.
The cluster distributions of rigid docking of theseNeoR6 andNeo-
r9 “second conformers” to gp120 and CXCR4 performed by
MolFit were similar to that obtained for the first used conformers
(seeMethods). This could be explained as follows: (i) The surfaces
of molecules in the MolFit have thickness about 2.5 Å which
allows some clashes between molecules, therefore the MolFit is
not so sensitive to different conformers; (ii) geometric–electro-
static version of MolFit prefers to take into consideration
electrostatic interactions between highly charged ligands and
receptors, rather than geometrically fitted conformations. More-
over, because starting rigid-body docking complexes were
relatively similar, the final flexible docking solutions also were
similar. For example, the second conformer of NeoR6 in its final
complex with gp120 at the CD4 binding site had similar
electrostatic contacts with gp120 residues (Asp338, Glu340,
Glu399, Asp427, Glu434 and Glu436) as the first conformer. The
interaction energy of this complex was of −289 kcal/mol versusinteraction energy of −283 kcal/mol of final complex formed by
the first conformer at the same region of gp120.
The binding free energies were calculated by MM-PBSA
method implemented in Amber9 program package [29,30]. The
summarized results are shown in Table 4. The binding free
energies for each pair of ligands constructed from different NMR
structures of neomycin B were similar, for example, −63.1 and
−65.4 kcal/mol for first and second conformers of NeoR6
complexed with wt-gp120IIIB, respectively. The increase of
binding free energy in complexes of NeoR6 with NeoR6res
gp120 IIIB (I341T and Q398K) was dramatic: from −63.1 to
−22.7 kcal/mol. The influence of NeoR6res mutations on binding
free energy ofNeo-r9–gp120 complexwas less significant than for
NeoR6–gp120 one, strengthening our hypothesis that Neo-r9 may
be a new HIV-1 attachment inhibitor, this should be further
investigated. The binding free energies of NeoR6 or Neo-r9
complexes with CXCR4 were consistently better than those of
NeoR6 or Neo-r9 complexes with wt-gp120IIIB. However, the
absolute values of binding free energies of NeoR6/Neo-r9
complexes with wt-gp120IIIB are also sufficient. This slight
preference of NeoR6/Neo-r9 to bind CXCR4 than gp120 could be
explained by the fact that negatively charged patch on gp120 at the
CD4 binding site is weaker and more distributed than negatively
charged surface of gp120 binding site of CXCR4. This is also
confirmed by geometrical comparison of conformational changes
of the ligands, especially of NeoR6. NeoR6 in complex with
CXCR4 has “sphere-like” conformation (Figs. 1b, 5e), while in
complex with gp120, it has more extended conformation (Fig. 4d)
with a few higher internal energy.
The mutations found in gp120 in the NeoR6res isolates were in
residues that differ, as far we know, from majority of those
described for viral isolates resistant to other CXCR4 inhibitors of
HIV-1 viral entry (Fig. 3a). Themutations in the gp120 gene of the
NeoR6 resistant HIV-1 isolates did not appear in the V3 loop of
gp120, as was found for other HIV-1 inhibitors of gp120–CXCR4
interaction [46,47].
One of the best known attachment inhibitors, BMS-378806,
exhibits potent inhibitory activity against both CCR5- and
CXCR4-tropic HIV-1 laboratory and clinical isolates, binds to
the CD4 binding cavity with a binding affinity similar to that of
soluble CD4 [48]. BMS-378806-selected resistant amino acid
substitutions were recently shown [4,48]. It was suggested that
BMS-378806 might interact with gp120 residues Met426 and
Met475 which are located at the CD4-binding cavity [48].
Changes in eight gp120 residues (including Met426, Leu125,
Lys429, Ala433, and Met475) caused resistance to BMS-378806
in an HXBc2 isolate [4]. Lin and coworkers [49,50] found the
following BMS-378806-resistant mutations: M426L, W427V,
Fig. 6. Putative gp41-binding site on gp120. The gp120 is shown as a ribbon.
The residues of the C1/C5 are shown in CPK representation (dark) and β3–β5
loop is colored gray.
Fig. 7. Schematicmodel illustrating the site of action ofNeoR6 that targets the gp41.
In the pre-hairpin intermediate state (left), N-region including HR1 is thought to
consist of a trimeric, parallel helical coiled-coil; the fusion peptide is inserted into the
host cell membrane; the C-region including HR2 is anchored to the viral membrane.
The fusogenic state of gp41 (right; based on of HIV-1 gp41 trimer modeled by M.
Caffrey (PDBentry 1if3, [66])) consists of a trimer of hairpins comprising an internal
trimeric, helical coiled-coil of the N-region surrounded by helices derived from C-
region. The fragment of the sequence of HR2 is labeled. The NeoR6-resistant
mutations S668R and F672Yare underlined. It is suggested thatNeoR6 targets a pre-
hairpin intermediate state in which the N- and C-regions of gp41 are not yet
associated. NeoR6 and gp41 trimer are presented as a proportions to their size. All
figures were prepared using InsightII.
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interacts with Glu399, corresponding to HXBc2 Lys429, and it is
very close to IIIB Leu95, Ala403, Met396 and Met445 (which
correspond to HXBc2 Leu125, Ala433, Met426 and Met475) in
the NeoR6–gp120 complex (Table 1). The docking of BMS-
378806 to relaxed crystal structure of HIV-1 YU2 gp120 revealed
that BMS-378806 binds gp120 at the CD4 binding cavity [51].
NeoR6 has contacts with IIIB Glu340 which corresponds to YU2
Glu370, common also with BMS-378806 binding. Whereas Neo-
r9 interacts with six residues (Glu370, Asn395, Met396, Trp397,
Val400, Gly401) common with BMS-378806 binding (Table 1),
suggesting that Neo-r9 may inhibit HIV-1-cell attachment. The
CD4 binding to gp120 induces the creation and/or exposure of the
hydrophobic groove in the gp41 HR1 trimeric coiled coil for
interaction with HR2 (or HR2-derived peptides) [52,53]. The
interaction between the gp41 HR1 and HR2 causes formation of
the fusogenic trimer. It was shown that BMS-378806 and its close
analog BMS-488043 dramatically inhibited HR2-derived peptide
C34 binding to the HR1 [52,53]. This clearly indicates that these
attachment inhibitors act on the pre-CD4-bound gp120 to prevent
subsequent CD4-gp120 interactions and the downstream events by
stabilization of unliganded gp120 conformation [53]. NeoR6 and
Neo-r9 probably bind CD4-binding site on gp120 in a similar
manner. Thus, we suppose that they may also prevent HR1–HR2
interaction and consequent structural changes in gp41–gp120
trimers.
As mentioned above, significant conformational changes in
gp120 occur upon CD4 binding. We checked if the residues
of gp120 are exposed during conformational transition from
unliganded conformation to CD4-bound one. For this purpose
we examined interaction of well-known fusion and entry
inhibitor T-20 with gp120 in two conformations. The 36-
amino-acid peptide T-20 corresponds to a sequence within the
HR2 of the gp41. It was thought that T-20 binds the gp41
HR1 and interferes with gp41 conformational changes
required for membrane fusion. However, it was found that
T-20 directly binds to the base of V3 loop and β19 strand of
CXCR4-using gp120 trimers at the CD4-bound conformation
[54]. The T-20–gp120 interaction affects the binding of some
antibodies to gp120 and blocks the interaction betweengp120–CD4 complexes and the CXCR4 receptor [54].
According to our approximate model of unliganded gp120
trimer, the base of V3 loop contacts with V1–V2 loops of
another protomer and it is not exposed to interaction with T-
20 or CXCR4 (Fig. 5a). After binding of CD4 to gp120 and
subsequent conformational changes, all residues of V3 loop
and β19 strand are exposed and available for direct
interaction with T-20 or CXCR4 (Fig. 5b, c). Importantly,
HR2 peptides can form amphipathic helices with a concen-
tration of highly conserved acidic residues along one face of
the helix [54]. This acidic face of T-20 probably binds the
basic V3 loop and β19 strand (which contains two basic
residues). Moreover, T-20 contains, at its C-terminus, a region
rich in Glu, Gln, Asp, and Asn residues, presenting
opportunities for the formation of salt bridges and hydrogen
bonds with gp120 [54]. CXCR4, as well as T-20, has many
acidic residues at the extracellular domains, which are
important for binding with gp120 V3 loop and β19 strand.
In contrast to T-20, NeoR6 probably binds HR2 (from which
T-20 is derived) as suggested by position of NeoR6-resistant
mutations in HR2 [16]. NeoR6 cannot bind V3 loop or β19
strand due to their highly positive, but it can interact with
acidic residues of CXCR4, preventing the gp120–CXCR4
binding. So, NeoR6 and T-20 both can interfere with gp120–
CXCR4 interaction, acting on opposite binding sites of this
complex.
The importance of the thirdNeoR6-resistant mutation S375L in
the gp120IIIB V4 loop is still questionable. On one hand, it was
shown that 5-amino-acid deletion 366-FNSTW-370 in gp120 V4
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On the other hand, tolerance of functional gp120 glycoproteins to
changes in the V4 loop of an HXBc2 isolate (including deletion of
the residues 400-WSTEGS-405; HXBc2 Ser405 corresponds to
IIIB Ser375) suggests that this region itself does not play a
significant role in the HIV-1 entry process [55].
The structure of the native gp41–gp120 complex is unknown,
however, there are numerous mutagenesis studies about putative
interactions between these proteins. Previous studies have
suggested that N-terminal (C1) and C-terminal (C5) regions
are important for association with gp41 [56,57]. The location of
the non-native engineered SOS disulfide mutation, which
stabilizes gp41–gp120 trimers, indicates that one of the contacts
of the C-terminal region (C5) is the gp41 C–C loop [58]. It was
proposed that β3–β5 loop of gp120, also interacts directly with
gp41 [59]. In our model of unliganded gp120 trimer all these
segments are adjacent to each other and form a continuous
surface, available for binding with gp41 (Fig. 6). Within gp41,
key determinants of the interaction with gp120 have been
demonstrated in the central ectodomain, flanking and including
the disulfide-bonded loop [e.g. [60,61]].
The structure of the ectodomain of gp41 in its fusogenic/post-
fusogenic conformation has been solved by NMR [62] and X-
rays crystallography [63], it consists of a trimer of hairpins
comprising an internal parallel trimeric coiled-coil of N-terminal
helices (residues 542–592 surrounded by antiparallel C-terminal
helices (residues 623–663) (right side of Fig. 7). However, these
structures do not contain more distal C-terminal regions, which
include the location of NeoR6-resistant mutations S668R and
F672Y. Moreover, known gp41 structures are in the fusogenic
trimer state, where contacts between N-terminal (HR1) and C-
terminal (HR2) regions already occurred, thus, inhibitors, such
as NeoR6 cannot interfere in this state. Although the monomeric
C-terminal fragment (residues 665–683, [64]), which includes
the location of NeoR6-resistant mutations and antiparallel 30 N-
terminal residues monomeric fragment [65] of gp41, were
resolved by NMR, construction of a reasonable overall trimeric
pre-hairpin intermediate model is still problematic. Prior to the
formation of the fusogenic trimer of hairpins, the ectodomain of
gp41 exists in a pre-hairpin intermediate state [67] (left side of
Fig. 7). In this state both the internal trimeric coiled-coil of N-
helices and the C-terminal region of gp41 ectodomain are
accessible to inhibitors [68,69]. For example, NCCG-gp41,
N34CCG, and N35CCG-N13 target the C region of gp41
ectodomain in a pre-hairpin intermediate state, thus preventing
formation of the fusogenic trimer of hairpins [68,69].We suggest
that NeoR6 also binds the C-terminal region of gp41 ectodomain
at the site where NeoR6-resistant mutations S668R and F672Y
appear, thus blocking the formation of the fusogenic trimer (Fig.
7). This hypothesis is supported especially by the fact that a
change of Ser668 to positively charged arginine causes
electrostatic repulsion with NeoR6. Interestingly, Glu659,
Glu662, and Asp664 (negatively charged residues that can
interact with a positively charged ligand) are located relatively
close to Ser668 and to Phe672, also supporting our suggestion
(Fig. 7). The second intriguing fact is that epitopes of the
neutralizing antibodies 2F5 (gp41 residues 662–667) and 4E10(671–676, mutation F672Y within this sequence) are also
situated in this region [21].
5. Conclusion
In order to predict the binding modes of new putative HIV-1
attachment inhibitors NeoR6 and Neo-r9, we performed a
multistep docking procedure including rigid body geometric–
electrostatic full scans by MolFit [27], consequent flexible ligand
docking by Autodock3 [28] of top-scoring representatives of
clusters found at the possible binding sites, and final refinement by
energy minimizations of the obtained complexes. Binding free
energies were calculated by MM-PBSA methodology. Construct-
ing a model of three CD4molecules bound gp120 trimer by the Cn
oligomer-forming algorithm [31] may provide additional infor-
mation in determination of putative gp120-CXCR4 binding site.
The structural models of unliganded HIV-1IIIB gp120, CXCR4–
gp120 trimer complex and interaction with HIV-1 inhibitors
(NeoR6 and Neo-r9) provide insight on their activity and can be
useful in structure based drug design studies for selective targeting
HIV-1 entry and/or other retroviruseswith similarmechanism(s) of
entry.
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